Point72 Europe London LLP Invests $872,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Point72 Europe London LLP acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 6,983 shares of the biotechnology company's stock, valued at approximately $872,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Innealta Capital LLC bought a new position in shares of Sarepta Therapeutics in the second quarter valued at $31,000. Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at $43,000. Huntington National Bank boosted its position in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares during the period. Riggs Asset Managment Co. Inc. increased its stake in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 75 shares in the last quarter. Finally, UMB Bank n.a. increased its stake in Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 197 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock traded down $4.60 on Friday, reaching $133.34. The stock had a trading volume of 777,554 shares, compared to its average volume of 1,375,611. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business's 50-day moving average price is $122.50 and its two-hundred day moving average price is $131.48. The stock has a market cap of $12.74 billion, a P/E ratio of 106.67 and a beta of 0.81. Sarepta Therapeutics, Inc. has a fifty-two week low of $78.67 and a fifty-two week high of $173.25.

Analyst Upgrades and Downgrades

Several brokerages have commented on SRPT. HC Wainwright started coverage on shares of Sarepta Therapeutics in a report on Monday, November 25th. They issued a "sell" rating and a $80.00 target price for the company. Barclays lowered their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating on the stock in a research report on Thursday, August 8th. Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a report on Wednesday. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a "buy" rating and a $165.00 price target on the stock. Finally, William Blair raised Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $175.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.